Brinn R, Brøsen K, Gram L F, Haghfelt T, Otton S V
Br J Clin Pharmacol. 1986 Aug;22(2):194-7. doi: 10.1111/j.1365-2125.1986.tb05250.x.
In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day-1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2- and 5-dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.
对8例患者在每日服用600 - 800毫克奎尼丁治疗1周前后立即进行了司巴丁试验。治疗前，1例患者被归类为代谢缓慢者（代谢率：大于或等于20），7例患者为代谢正常者。在奎尼丁治疗期间，司巴丁代谢物（2 - 和5 - 脱氢司巴丁）的形成几乎完全被抑制。最初被归类为代谢正常者的患者在奎尼丁治疗期间表现出代谢缓慢者的表型。
